Organogenesis Holdings Net Income
| ORGO Stock | USD 3.83 0.06 1.59% |
As of the 10th of February, Organogenesis Holdings holds the Semi Deviation of 3.79, risk adjusted performance of 0.0303, and Coefficient Of Variation of 3747.95. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Organogenesis Holdings, as well as the relationship between them.
Organogenesis Holdings Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.2621 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 990.1 K | 935.2 K | |
| Net Income Applicable To Common Shares | 17.9 M | 18.8 M | |
| Net Income | 990.1 K | 1 M | |
| Net Income Per Share | 0.01 | 0.01 | |
| Net Loss | (0.35) | (0.34) |
Organogenesis | Net Income | Build AI portfolio with Organogenesis Stock |
Evaluating Organogenesis Holdings's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Organogenesis Holdings's fundamental strength.
Latest Organogenesis Holdings' Net Income Growth Pattern
Below is the plot of the Net Income of Organogenesis Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Organogenesis Holdings financial statement analysis. It represents the amount of money remaining after all of Organogenesis Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Organogenesis Holdings' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Organogenesis Holdings' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 861 K | 10 Years Trend |
|
Net Income |
| Timeline |
Organogenesis Net Income Regression Statistics
| Arithmetic Mean | 1,521,030 | |
| Geometric Mean | 1,070,477 | |
| Coefficient Of Variation | 2,021 | |
| Mean Deviation | 14,803,398 | |
| Median | (25,160) | |
| Standard Deviation | 30,734,919 | |
| Sample Variance | 944.6T | |
| Range | 159M | |
| R-Value | 0.17 | |
| Mean Square Error | 980T | |
| R-Squared | 0.03 | |
| Significance | 0.53 | |
| Slope | 1,007,381 | |
| Total Sum of Squares | 15114.2T |
Organogenesis Net Income History
Other Fundumenentals of Organogenesis Holdings
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Organogenesis Holdings Net Income component correlations
Organogenesis Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Organogenesis Holdings is extremely important. It helps to project a fair market value of Organogenesis Stock properly, considering its historical fundamentals such as Net Income. Since Organogenesis Holdings' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Organogenesis Holdings' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Organogenesis Holdings' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Organogenesis diversify its offerings? Factors like these will boost the valuation of Organogenesis Holdings. Anticipated expansion of Organogenesis directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Organogenesis Holdings data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.222 | Earnings Share (0.08) | Revenue Per Share | Quarterly Revenue Growth 0.31 | Return On Assets |
Investors evaluate Organogenesis Holdings using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Organogenesis Holdings' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Organogenesis Holdings' market price to deviate significantly from intrinsic value.
It's important to distinguish between Organogenesis Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Organogenesis Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Organogenesis Holdings' market price signifies the transaction level at which participants voluntarily complete trades.
Organogenesis Holdings 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Organogenesis Holdings' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Organogenesis Holdings.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Organogenesis Holdings on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Organogenesis Holdings or generate 0.0% return on investment in Organogenesis Holdings over 90 days. Organogenesis Holdings is related to or competes with SNDL, Monopar Therapeutics, Emergent Biosolutions, Esperion Therapeutics, Evolus, SIGA Technologies, and AngioDynamics. Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for th... More
Organogenesis Holdings Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Organogenesis Holdings' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Organogenesis Holdings upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.97 | |||
| Information Ratio | 0.0126 | |||
| Maximum Drawdown | 55.15 | |||
| Value At Risk | (7.07) | |||
| Potential Upside | 9.18 |
Organogenesis Holdings Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Organogenesis Holdings' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Organogenesis Holdings' standard deviation. In reality, there are many statistical measures that can use Organogenesis Holdings historical prices to predict the future Organogenesis Holdings' volatility.| Risk Adjusted Performance | 0.0303 | |||
| Jensen Alpha | 0.0416 | |||
| Total Risk Alpha | (0.59) | |||
| Sortino Ratio | 0.0223 | |||
| Treynor Ratio | 0.1156 |
Organogenesis Holdings February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0303 | |||
| Market Risk Adjusted Performance | 0.1256 | |||
| Mean Deviation | 3.7 | |||
| Semi Deviation | 3.79 | |||
| Downside Deviation | 3.97 | |||
| Coefficient Of Variation | 3747.95 | |||
| Standard Deviation | 7.0 | |||
| Variance | 48.95 | |||
| Information Ratio | 0.0126 | |||
| Jensen Alpha | 0.0416 | |||
| Total Risk Alpha | (0.59) | |||
| Sortino Ratio | 0.0223 | |||
| Treynor Ratio | 0.1156 | |||
| Maximum Drawdown | 55.15 | |||
| Value At Risk | (7.07) | |||
| Potential Upside | 9.18 | |||
| Downside Variance | 15.75 | |||
| Semi Variance | 14.38 | |||
| Expected Short fall | (5.07) | |||
| Skewness | 4.18 | |||
| Kurtosis | 25.41 |
Organogenesis Holdings Backtested Returns
Organogenesis Holdings maintains Sharpe Ratio (i.e., Efficiency) of -0.21, which implies the firm had a -0.21 % return per unit of risk over the last 3 months. Organogenesis Holdings exposes twenty-eight different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Organogenesis Holdings' Coefficient Of Variation of 3747.95, risk adjusted performance of 0.0303, and Semi Deviation of 3.79 to confirm the risk estimate we provide. The company holds a Beta of 1.53, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Organogenesis Holdings will likely underperform. At this point, Organogenesis Holdings has a negative expected return of -0.8%. Please make sure to check Organogenesis Holdings' downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Organogenesis Holdings performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.68 |
Good predictability
Organogenesis Holdings has good predictability. Overlapping area represents the amount of predictability between Organogenesis Holdings time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Organogenesis Holdings price movement. The serial correlation of 0.68 indicates that around 68.0% of current Organogenesis Holdings price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.68 | |
| Spearman Rank Test | 0.34 | |
| Residual Average | 0.0 | |
| Price Variance | 0.17 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Organogenesis Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Organogenesis Holdings reported net income of 861 K. This is 99.75% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 99.85% higher than that of the company.
Organogenesis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Organogenesis Holdings' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Organogenesis Holdings could also be used in its relative valuation, which is a method of valuing Organogenesis Holdings by comparing valuation metrics of similar companies.Organogenesis Holdings is currently under evaluation in net income category among its peers.
Organogenesis Holdings Current Valuation Drivers
We derive many important indicators used in calculating different scores of Organogenesis Holdings from analyzing Organogenesis Holdings' financial statements. These drivers represent accounts that assess Organogenesis Holdings' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Organogenesis Holdings' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 1.2B | 349.9M | 536.7M | 421.4M | 484.6M | 699.2M | |
| Enterprise Value | 1.2B | 371.2M | 551.7M | 329.1M | 378.5M | 707.3M |
Organogenesis Holdings ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Organogenesis Holdings' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Organogenesis Holdings' managers, analysts, and investors.Environmental | Governance | Social |
Organogenesis Holdings Institutional Holders
Institutional Holdings refers to the ownership stake in Organogenesis Holdings that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Organogenesis Holdings' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Organogenesis Holdings' value.| Shares | Renaissance Technologies Corp | 2025-06-30 | 803.9 K | Northern Trust Corp | 2025-06-30 | 788.2 K | Aqr Capital Management Llc | 2025-06-30 | 717.1 K | D. E. Shaw & Co Lp | 2025-06-30 | 613.1 K | Connor Clark & Lunn Inv Mgmt Ltd | 2025-06-30 | 593.2 K | State Of Wisconsin Investment Board | 2025-06-30 | 527.2 K | Ubs Group Ag | 2025-06-30 | 499.4 K | Bank Of America Corp | 2025-06-30 | 480.8 K | Wellington Management Company Llp | 2025-06-30 | 419.4 K | Soleus Capital Management, L.p. | 2025-06-30 | 12.3 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 12.1 M |
Organogenesis Fundamentals
| Return On Equity | 0.003 | ||||
| Return On Asset | 0.0018 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 586.37 M | ||||
| Shares Outstanding | 126.91 M | ||||
| Shares Owned By Insiders | 46.69 % | ||||
| Shares Owned By Institutions | 54.94 % | ||||
| Number Of Shares Shorted | 12.89 M | ||||
| Price To Earning | 17.12 X | ||||
| Price To Book | 1.88 X | ||||
| Price To Sales | 1.04 X | ||||
| Revenue | 482.04 M | ||||
| Gross Profit | 346.56 M | ||||
| EBITDA | 15.76 M | ||||
| Net Income | 861 K | ||||
| Cash And Equivalents | 113.24 M | ||||
| Cash Per Share | 0.87 X | ||||
| Total Debt | 43.31 M | ||||
| Debt To Equity | 0.52 % | ||||
| Current Ratio | 2.62 X | ||||
| Book Value Per Share | 2.01 X | ||||
| Cash Flow From Operations | 14.21 M | ||||
| Short Ratio | 9.58 X | ||||
| Earnings Per Share | (0.08) X | ||||
| Price To Earnings To Growth | 6.15 X | ||||
| Target Price | 8.5 | ||||
| Number Of Employees | 869 | ||||
| Beta | 1.4 | ||||
| Market Capitalization | 486.07 M | ||||
| Total Asset | 497.89 M | ||||
| Retained Earnings | (40.11 M) | ||||
| Working Capital | 208.46 M | ||||
| Current Asset | 24.47 M | ||||
| Current Liabilities | 23.22 M | ||||
| Net Asset | 497.89 M |
About Organogenesis Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Organogenesis Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Organogenesis Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Organogenesis Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Organogenesis Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.Moving together with Organogenesis Stock
Moving against Organogenesis Stock
| 0.51 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.44 | DSGN | Design Therapeutics | PairCorr |
| 0.43 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.36 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.35 | ENGN | enGene Holdings Common | PairCorr |
The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.
The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Will Biotechnology sector continue expanding? Could Organogenesis diversify its offerings? Factors like these will boost the valuation of Organogenesis Holdings. Anticipated expansion of Organogenesis directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Organogenesis Holdings data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.222 | Earnings Share (0.08) | Revenue Per Share | Quarterly Revenue Growth 0.31 | Return On Assets |
Investors evaluate Organogenesis Holdings using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Organogenesis Holdings' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Organogenesis Holdings' market price to deviate significantly from intrinsic value.
It's important to distinguish between Organogenesis Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Organogenesis Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Organogenesis Holdings' market price signifies the transaction level at which participants voluntarily complete trades.